HAE Stock Recent News

Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.

Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema

Haemonetics Corporation (NYSE:HAE ) Q4 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Olga Guyette – Vice President-Investor Relations & Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Rohin Patel – JPMorgan Marie Thibault – BTIG Mike Matson – Needham & Company Andrew Cooper – Raymond James Joanne Wuensch – Citi Anthony Petrone – Mizuho Financial Group Michael Petusky – Barrington Research Craig Bijou – Bank of America Securities Operator Good day, and thank you for standing by. Welcome to the Q4 2025 Haemonetics Corporation Earnings Conference Call.

The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Haemonetics (HAE) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.90 per share a year ago.

Financial release accessible online BOSTON , May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were interested in trying a new prophylactic therapy, with nearly two-thirds (65%) reporting they haven't yet found the best treatment option for them. The Ionis-sponsored survey was conducted online by The Harris Poll among 150 adults living with HAE and 228 allergists/immunologists who see HAE patien.